Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival
Sign Up to like & getrecommendations! Published in 2017 at "Blood Cancer Journal"
DOI: 10.1038/bcj.2017.76
Abstract: The recent remarkable advances in multiple myeloma (MM) therapy and outcomes have had mixed impact on patients with adverse risk genetics, many of whom continue to have inferior outcomes. This applies particularly to deletion of… read more here.
Keywords: del 17p; timing tp53; prevalence timing; tp53 mutations ... See more keywords
Detection of Clinically Relevant Molecular Alterations in Chronic Lymphocytic Leukemia (CLL) By Nanopore Sequencing
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-110948
Abstract: Introduction Chronic Lymphocytic Leukaemia (CLL) is the most prevalent leukaemia in the Western world and characterised by clinical heterogeneity. IgHV mutation status, mutations in the TP53 gene and deletions of the p-arm of chromosome 17… read more here.
Keywords: sample; cll; detection; del 17p ... See more keywords
Impact of Acquired Del(17p) in Patients with Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-115458
Abstract: Introduction Del(17p) detected by fluorescence in situ hybridisation (FISH) of bone marrow plasma cells (BMPCs) is an adverse prognostic factor in patients with multiple myeloma (MM). While the natural history and prognostic factors in patients… read more here.
Keywords: del 17p; research; membership entity; research funding ... See more keywords
Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-136242
Abstract: Introduction: Increased understanding of the pathophysiology of multiple myeloma (MM) and the introduction of new drugs has led to considerable survival improvements in recent years. The International Myeloma Working Group consensus recently updated the definition… read more here.
Keywords: high risk; del 17p; research funding;
Acquired Chromosomal Abnormalities t(14;16), Del(17p) or Del(13q) after Receiving Chemotherapies Predict the Poor Prognosis of Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.3116.3116
Abstract: Introduction: Multiple myeloma (MM) is known as heterogeneous disease characterized by the clonal proliferation of tumor plasma cells. Recently, the prognosis of MM is classified depending on the appearance of cytogenetic abnormalities. However, no publication… read more here.
Keywords: del 17p; 17p del; prognosis; del 13q ... See more keywords
17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
Sign Up to like & getrecommendations! Published in 2019 at "Journal for Immunotherapy of Cancer"
DOI: 10.1186/s40425-019-0509-0
Abstract: Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic gold standard for more than 2 decades in this pathology, when used in combination with… read more here.
Keywords: rituximab; del 17p; lymphocytic leukemia; chronic lymphocytic ... See more keywords
Clinical features of patients with multiple myeloma harboring t(4;14) and impact on long-term survival.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2022.40.16_suppl.8062
Abstract: 8062 Background: Translocation (4;14) is a known adverse prognostic factor in myeloma. However, utilization of proteasome inhibitors (PIs) in myeloma has abrogated the negative impact of t(4;14) in myeloma, and some investigators question whether t(4;14)… read more here.
Keywords: long term; maintenance; del 17p; impact ... See more keywords
Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p).
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.18722
Abstract: We analyzed the treatment of newly diagnosed and relapsed/refractory multiple myeloma (NDMM/RRMM) patients with del(17p). Thirteen prospective studies that evaluated 3,187 MM patients, including 685with del(17p), were included in our meta-analysis. The incidence of del(17p)… read more here.
Keywords: del 17p; newly diagnosed; rrmm patients; dexamethasone ... See more keywords
Optimizing therapy for del(17p) multiple myeloma
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.22987
Abstract: We read with interest the publication by Liu et al. reporting the results from a meta‐analysis of 13 prospective studies evaluating the efficacy of proteasome inhibitor/immunomodulatory drug‐based treatments for newly diagnosed (ND) and relapsed/ refractory… read more here.
Keywords: del; pfs; del 17p; rrmm patients ... See more keywords
Relevance of newly acquired mutations to the prognosis of patients with relapsed multiple myeloma.
Sign Up to like & getrecommendations! Published in 2020 at "Polish archives of internal medicine"
DOI: 10.20452/pamw.15446
Abstract: 473 serial FISH testing at diagnosis and relapse. Cy‐ togenetic evolution was defined as the acquisition or loss of a cytogenetic abnormality at the sec‐ ond FISH testing and was observed in 14 patients (48%).… read more here.
Keywords: medicine; del 17p; evolution; prognosis ... See more keywords
Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion
Sign Up to like & getrecommendations! Published in 2020 at "Haematologica"
DOI: 10.3324/haematol.2020.259432
Abstract: Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma whose tumors carry deletion of chromosome 17p13.1 [del(17p)] have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy. Zanubrutinib is a selective next-generation Bruton tyrosine kinase… read more here.
Keywords: del 17p; lymphocytic leukemia; treatment; deletion ... See more keywords